These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 35843148)

  • 1. A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.
    Noori M; Azizi S; Abbasi Varaki F; Nejadghaderi SA; Bashash D
    Int Immunopharmacol; 2022 Sep; 110():109046. PubMed ID: 35843148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of COVID-19 Vaccines in Patients with Hematological Malignancy Compared to Healthy Controls: A Systematic Review and Meta-analysis.
    Das Barshan A; Matsumoto-Takahashi ELA
    JMA J; 2024 Apr; 7(2):153-171. PubMed ID: 38721084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination.
    Guven DC; Sahin TK; Akın S; Uckun FM
    Oncologist; 2022 Apr; 27(4):e357-e361. PubMed ID: 35274729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis.
    Martins-Branco D; Nader-Marta G; Tecic Vuger A; Debien V; Ameye L; Brandão M; Punie K; Loizidou A; Willard-Gallo K; Spilleboudt C; Awada A; Piccart M; de Azambuja E
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3075-3080. PubMed ID: 35867203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination for SARS-CoV-2 in Hematological Patients.
    Riccardi N; Falcone M; Yahav D
    Acta Haematol; 2022; 145(3):257-266. PubMed ID: 35220303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis.
    Gagelmann N; Passamonti F; Wolschke C; Massoud R; Niederwieser C; Adjallé R; Mora B; Ayuk F; Kröger N
    Haematologica; 2022 Aug; 107(8):1840-1849. PubMed ID: 34911284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of serological response to anti-SARS-CoV-2 mRNA vaccination in hematological patients.
    Pascale SP; Nuccorini R; Pierri T; Di Mare R; Fabio L; Lerose E; Merlino MA; Schiavo P; Amendola A; Brucoli G; Caputo MD; Chitarrelli I; Cimminiello M; Coluzzi S; Filardi NB; Matturro A; Vertone D; Poggiaspalla M; Malaspina F; Musuraca G; Coralluzzo G; Mannarella C; Musto C; Bellettieri AP; Martinelli G; Cerchione C; Pizzuti M
    Front Immunol; 2022; 13():892331. PubMed ID: 36003404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes.
    Guo W; Zheng Y; Feng S
    Front Cell Infect Microbiol; 2023; 13():1207225. PubMed ID: 37928188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seroconversion following the first, second, and third dose of SARS-CoV-2 vaccines in immunocompromised population: a systematic review and meta-analysis.
    Mehrabi Nejad MM; Shobeiri P; Dehghanbanadaki H; Tabary M; Aryannejad A; Haji Ghadery A; Shabani M; Moosaie F; SeyedAlinaghi S; Rezaei N
    Virol J; 2022 Aug; 19(1):132. PubMed ID: 35941646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis.
    Becerril-Gaitan A; Vaca-Cartagena BF; Ferrigno AS; Mesa-Chavez F; Barrientos-Gutiérrez T; Tagliamento M; Lambertini M; Villarreal-Garza C
    Eur J Cancer; 2022 Jan; 160():243-260. PubMed ID: 34794855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis.
    Uaprasert N; Pitakkitnukun P; Tangcheewinsirikul N; Chiasakul T; Rojnuckarin P
    Blood Cancer J; 2022 Dec; 12(12):173. PubMed ID: 36550105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients.
    Piñana JL; Rodríguez-Belenguer P; Caballero D; Martino R; Lopez-Corral L; Terol MJ; Vazquez L; Calabuig M; Sanz-Linares G; Marin-Jimenez F; Alonso C; Montoro J; Ferrer E; Facal A; Pascual MJ; Rodriguez-Fernandez A; Olave MT; Cascales-Hernandez A; Gago B; Hernández-Rivas JÁ; Villalon L; Corona M; Roldán-Pérez A; Ribes-Amoros J; González-Santillana C; Garcia-Sanz R; Navarro D; Serrano-López AJ; Cedillo Á; Soria-Olivas E; Sureda A; Solano C;
    Ann Hematol; 2022 Sep; 101(9):2053-2067. PubMed ID: 35780254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis.
    Teh JSK; Coussement J; Neoh ZCF; Spelman T; Lazarakis S; Slavin MA; Teh BW
    Blood Adv; 2022 Apr; 6(7):2014-2034. PubMed ID: 34852173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic Lymphocytic Leukemia in the SARS-CoV-2 Pandemic.
    Arellano-Llamas AA; Vela-Ojeda J; Hernandez-Caballero A
    Curr Oncol Rep; 2022 Feb; 24(2):209-213. PubMed ID: 35061199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: Systematic review and meta-analysis.
    Rinaldi I; Pratama S; Wiyono L; Tandaju JR; Wardhana IL; Winston K
    Front Oncol; 2022; 12():951215. PubMed ID: 36003763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study.
    Corradini P; Agrati C; Apolone G; Mantovani A; Giannarelli D; Marasco V; Bordoni V; Sacchi A; Matusali G; Salvarani C; Zinzani PL; Mantegazza R; Tagliavini F; Lupo-Stanghellini MT; Ciceri F; Damian S; Uccelli A; Fenoglio D; Silvestris N; Baldanti F; Piaggio G; Ciliberto G; Morrone A; Locatelli F; Sinno V; Rescigno M; Costantini M;
    Clin Infect Dis; 2023 Feb; 76(3):e426-e438. PubMed ID: 35607769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral and cellular immune responses after three or four doses of BNT162b2 in patients with hematological malignancies.
    Heftdal LD; Hamm SR; Pérez-Alós L; Madsen JR; Armenteros JJA; Fogh K; Kronborg CC; Vallentin AP; Hasselbalch RB; Møller DL; Hansen CB; Pries-Heje M; Gang AO; Ostrowski SR; Frikke-Schmidt R; Sørensen E; Hilsted L; Bundgaard H; Iversen K; Garred P; Nielsen SD; Grønbaek K
    Eur J Haematol; 2023 Aug; 111(2):229-239. PubMed ID: 37151174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of cellular and humoral immunogenicity and effectiveness of SARS-CoV-2 booster vaccination in hematologic neoplasms.
    Jiménez M; Fernández-Naval C; Navarro V; Novoa S; Martinez-Gallo M; Medina D; Andrés C; Antón A; Peralta S; Pujadas G; Hernández C; Pagès C; Roldán E; Pumarola T; Gironella M; Ruiz-Camps I; Martínez-Gómez X; Valcárcel D; Hernández M; Bosch F; Crespo M; Esperalba J; Abrisqueta P
    Am J Hematol; 2023 Aug; 98(8):1204-1213. PubMed ID: 37151135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.
    Herishanu Y; Avivi I; Aharon A; Shefer G; Levi S; Bronstein Y; Morales M; Ziv T; Shorer Arbel Y; Scarfò L; Joffe E; Perry C; Ghia P
    Blood; 2021 Jun; 137(23):3165-3173. PubMed ID: 33861303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.